Romiplostim: all 88 studies that test it
Page 1 of 1. Open to participants first (28), then studies with results posted, then the rest; newest registration first within each.
- Combination Therapy of Romiplostim and Erythropoiesis-stimulating AgentsRecruitingNCT07854561Phase 2
- Efficacy and Safety of Romiplostim N01 for Injection in Promoting Platelet Reconstitution After Allogeneic Hematopoietic Stem Cell TransplantationNot yet recruitingNCT07829952Phase 2
- Romiplostim N01 for Injection for Secondary Prophylaxis of CIT in Breast CancerNot yet recruitingNCT07771881Phase 2
- A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP)RecruitingNCT07700238Phase 3
- Romiplostim for Oral TPO-RA Resistant ITPRecruitingNCT07612319Not applicable
- Romiplostim N01 in Chemoradiotherapy-induced Aplastic AnemiaNot yet recruitingNCT07572084Phase 2
- CsA+EPAG/HPAG+Romiplostim N01 in Newly-diagnosed SAA/TD-NSAANot yet recruitingNCT07558434Phase 2
- Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AARecruitingNCT07400341Phase 2
- Phase II Study of Orelabrutinib in Combination With Romiplostim N01 in Patients With Primary Immune Thrombocytopenia (ITP) Who Have Received At Least One Prior Line of TherapyNot yet recruitingNCT07400250Phase 2
- A Study of Romiplostim N01 Plus IST vs. Placebo Plus IST for Treatment-Naive Severe Aplastic AnemiaNot yet recruitingNCT07345000Phase 3
- Romiplostim N01 for Platelet Recovery After Haploidentical HSCTRecruitingNCT07321626Phase 1
- Preoperative Use of Romiplostim in Thrombocytopenic Patients Undergoing Cardiac Surgery.RecruitingNCT07278661Phase 2
- Efficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune ThrombocytopeniaRecruitingNCT07206823Not applicable
- A Multicenter, Open-label, Randomized Controlled Trial Evaluating the Efficacy and Safety of Romiplostim N01 in the Treatment of Thrombocytopenia Associated With Concurrent/Sequential Chemoradiotherapy and Chemotherapy Combined With/Without Immunotherapy in Solid TumorsNot yet recruitingNCT07185893Not applicable
- Romiplostim N01 in the Treatment of Thrombocytopenia Caused by Cytotoxic Drugs in Breast Cancer PatientsNot yet recruitingNCT07162519Not applicable
- Romiplostim N01 for the Treatment of Thrombocytopenia Associated With Radiotherapy-Combined Treatment Regimens in Patients With Solid TumorsNot yet recruitingNCT07128576Phase 2
- Romiplostim N01 for Chemotherapy-induced ThrombocytopeniaRecruitingNCT07063225Phase 2
- Single Arm Romiplostim to Prevent CITRecruitingNCT07048249Early Phase 1
- Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer PatientsRecruitingNCT07043894Phase 2
- Efficacy and Safety Study of Romiplostim N01 for Cancer Treatment-induced Thrombocytopenia (CTIT) in the Treatment of LeukemiaRecruitingNCT06898983Phase 2
- A Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11RecruitingNCT06759636Phase 3
- Romiplostim N01 for Platelet Recovery in Adult Hematologic Malignancies Patients Undergoing UCBTRecruitingNCT06693791Phase 2
- A Study of Romiplostim for the Treatment of Refractory Transfusion-dependent NSAANot yet recruitingNCT06535685Phase 4
- Ropustin for Refractory Aplastic Anaemia After Radiotherapy - a Single-centre, Prospective, Open-label, Single-arm StudyNot yet recruitingNCT06516484Phase 4
- A Multicenter Randomized Controlled Study on the Treatment of Refractory CTIT With Romiplostim N01 Compared to Recombinant Human ThrombopoietinNot yet recruitingNCT06440824Phase 3
- Romiplostim in Chemotherapy-Induced ThrombocytopeniaRecruitingNCT06201663Phase 3
- Romiplostim in Combination With CsA vs. CsA in the Treatment of Newly Diagnosed NSAANot yet recruitingNCT06009497Phase 4
- Immune Thrombocytopenia Management in AdultsRecruitingNCT05861297Phase 4
- A Study of Romiplostim to Prevent Low Platelet Counts in Children and Young Adults Receiving Chemotherapy for Solid TumorsTerminatedNCT04671901Phase 2Results posted
- Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood CancerCompletedNCT04478123Phase 2Results posted
- Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal CancerCompletedNCT03362177Phase 3Results posted
- Validation of a Predictive Model of Response to Romiplostim in Patients With IPSS Low or Intermediate-1 Risk MDS and ThrombocytopeniaCompletedNCT02335268Phase 2Results posted
- Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)CompletedNCT02279173Phase 3Results posted
- A Phase 2 Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic AnemiaCompletedNCT02094417Phase 2Results posted
- Study of Romiplostim for Chemotherapy Induced ThrombocytopeniaCompletedNCT02052882Phase 2Results posted
- Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving ChemotherapyTerminatedNCT01676961Phase 2Results posted
- Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric PatientsCompletedNCT01444417Phase 3Results posted
- Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving RomiplostimCompletedNCT01143038Phase 2Results posted
- A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia PurpuraCompletedNCT01071954Phase 3Results posted
- Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP)CompletedNCT00907478Phase 4Results posted
- Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP)CompletedNCT00902018Phase 2Results posted
- Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)CompletedNCT00614523Phase 2Results posted
- Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric SubjectsCompletedNCT00515203Phase 1/2Results posted
- An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITPCompletedNCT00508820Phase 3Results posted
- Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS)CompletedNCT00472290Not applicableResults posted
- Open Label Extension Study of AMG 531 in Japanese Subjects With ITPCompletedNCT00440037Phase 2/3Results posted
- A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving RevlimidCompletedNCT00418665Phase 2Results posted
- Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic PurpuraCompletedNCT00415532Phase 3Results posted
- Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00413283Phase 2Results posted
- Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating AgentsCompletedNCT00321711Phase 2Results posted
- Determination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodysplastic Syndromes (MDS)CompletedNCT00303472Phase 2Results posted
- Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's LymphomaCompletedNCT00299182Phase 1/2Results posted
- A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With LymphomaCompletedNCT00283439Phase 1/2Results posted
- AMG 531 in Patients With Advanced Malignancy Receiving Treatment With CarboplatinCompletedNCT00147225Phase 1/2Results posted
- Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)CompletedNCT00117143Phase 1/2Results posted
- Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)CompletedNCT00116688Phase 3Results posted
- Evaluating the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)CompletedNCT00111475Phase 2Results posted
- Romiplostim N01 in the Treatment of Refractory Chemoradiotherapy-induced AAWithdrawnNCT07532408Phase 2
- CsA+EPAG/HPAG+Romiplostim N01 in the Treatment of Newly-diagnosed SAA/TD-NSAAWithdrawnNCT07523009Phase 2
- Study of Efficacy, Safety and Immunogenicity of GP40141 (GEROPHARM, Russia) in Patients With Immune ThrombocytopeniaActive, not recruitingNCT06497036Phase 3
- Double-blind, Randomized Comparative Cross-sectional Study of Pharmacodynamics and Pharmacokinetics of Drugs GP40141Status unknownNCT05652595Phase 1
- Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP PatientsCompletedNCT05492409Phase 3
- Romiplostim Plus Dexamethasone vs Dexamethasone in Patients With Newly Diagnosed Primary Immune ThrombocytopeniaActive, not recruitingNCT05325593Phase 3
- Comparative Study of Clinical Efficacy and Safety of GNR-069 and Nplate in Patients With ITPCompletedNCT05220878Phase 3
- Phase II Trial of Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-meth GlioblastomaWithdrawnNCT04933942Phase 2
- Using Romiplostim to Treat Low Platelet Counts During Chemotherapy in People With LymphomaCompletedNCT04673266Phase 2
- Romiplostim, Rituximab and Dexamethasone as Frontline Treatment for Immune ThrombocytopeniaStatus unknownNCT04588194Phase 2
- TPO-Mimetic Use in Children for Hematopoietic FailureCompletedNCT04478227Early Phase 1
- Efficacy and Safety of Romiplostim Versus Eltrombopag in the Treatment of Thrombocytopenia in Patients With Wiskott-Aldrich SyndromeStatus unknownNCT04371939Phase 2
- Phase II Trial of Romiplostim With Danazol in Patients With Eltrombopag-resistant Immune ThrombocytopeniaStatus unknownNCT04289207Phase 2
- Study of AMG531 (Romiplostim) in Patients With Aplastic AnemiaCompletedNCT04095936Phase 2/3
- Study of AMG531(Romiplostim) in Patients With Aplastic AnemiaCompletedNCT03957694Phase 2/3
- Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast CancerActive, not recruitingNCT03937154Phase 3
- Patients With Relapsed Ovarian Cancer (2nd and 3rd Line) Treated With Chemotherapy According to AGO GuidelinesTerminatedNCT03622931Phase 2
- Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Lymphoma.WithdrawnNCT03343847Phase 3
- Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Immune Thrombocytopenia (ITP)CompletedNCT02868099Phase 3
- Evaluating the Pharmacokinetics and Pharmacodynamics of Romiplostim in Patients With Immune Thrombocytopenia (ITP)CompletedNCT02868060Phase 1/2
- Study of Romiplostim(AMG531) in Subjects With Aplastic AnemiaCompletedNCT02773290Phase 2/3
- Immunomodulation With Romiplostim in Young Adults With ITPCompletedNCT02760251Phase 4
- An Observational Study to Evaluate the Efficacy of Biweekly Romiplostim in Adult Patients With ITPStatus unknownNCT02338414Phase 2
- Prevention of Thrombocytopenia in Glioblastoma PatientsTerminatedNCT02227576Phase 2
- Safety of Romiplostim (Nplate®) Following UCBTCompletedNCT02046291Phase 1
- Using ROMIPLOSTINE for Persistent Thrombocytopenia With Transfusion-dependent Patients Who Received Allogeneic Hematopoietic Stem CellCompletedNCT01980030Phase 1/2
- Secondary Prophylaxis in Non-Hodgkin Lymphoma (NHL) and Chemotherapy-induced ThrombocytopeniaCompletedNCT01516619Phase 2
- Romiplostim in Treating Hepatitis C-Infected Patients With ThrombocytopeniaTerminatedNCT01153919Phase 2
- Safety Study of AMG 531 in Japanese Subjects With ITPCompletedNCT00305435Phase 2
- AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to SplenectomyCompletedNCT00102336Phase 3
- AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to SplenectomyCompletedNCT00102323Phase 3